Evidence map›Paper›PMID 41287182›Full record

ReviewRenal failure2025

Pyroptosis-induced tissue damage in kidney disease.

Zhiyuan Zhang, Xiaodi Li, Yang Han, Mianzhi Zhang

Abstract readReview
In one paragraph

Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhiyuan ZhangTianjin University of Traditional Chinese Medicine, Tianjin, China.
Xiaodi LiTianjin University of Traditional Chinese Medicine, Tianjin, China.
Yang HanTianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
Mianzhi ZhangTianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyroptosis is a form of programmed cell death that differs mechanistically from apoptosis and is characterized by a robust inflammatory response. It is primarily mediated by proteins of the gasdermin family, which form pores in the cell membrane, leading to osmotic cell lysis and the release of pro-inflammatory cytokines. As a process triggered by various pathological stimuli like infection, inflammation, and oxidative stress, pyroptosis contributes to a range of diseases, including autoimmune disorders and cancer. Evidence indicates that pyroptosis, a crucial innate immune component, promotes host defense by facilitating immune cell recruitment and tissue repair. However, dysregulated pyroptosis is a key driver of pathology, contributing to chronic inflammation, fibrosis, and tissue damage in a range of conditions such as kidney, cardiovascular, and metabolic disorders. More evidence suggests that pyroptosis may dominate the process of irreversible damage to renal tissue and may accelerate the time for patients to enter end-stage renal disease. At present, when diagnosing kidney diseases and performing kidney biopsy, more attention is paid to the extent of kidney tissue damage, which is strongly related to the prognosis of patients. Given that many kidney diseases, especially acute kidney injury, involve inflammatory responses, targeting dysregulated pyroptosis presents a potential strategy for alleviating irreversible renal damage. This review will provide a detailed description of the signaling pathways of pyroptosis, with a focus on the mechanisms of pyroptosis-induced renal tissue damage and new advances in treatment.

Indexed as

Acute Kidney InjuryKidneyKidney DiseasesPyroptosisAnimalsHumansInflammationOxidative StressSignal Transductionacute kidney injuryglomerular endothelial cellskidney tissuepodocytePyroptosisrenal tubule

Identifiers

PMID41287182
PMCPMC12649778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.